Enanta Pharmaceuticals, Inc., (NASDAQ: ENTA), a research and
development-focused biotechnology company dedicated to creating small
molecule drugs in the infectious disease field, today announced that
Enanta management will present at two investor conferences during the
month of September.
Members of Enanta senior management will participate at the following
investor conferences:
-
Morgan Stanley Global Healthcare Conference, Wednesday, September 11
at 1:30 p.m. ET., New York
-
Format: Brief remarks by management followed by Q&A from analyst
-
Stifel 2013 Healthcare Conference, Thursday, September 12 at 4:25 p.m.
ET., Boston
-
Format: Formal presentation followed by Q&A from analyst
A live audio webcast and replay of the presentations can be accessed by
visiting the Investor homepage section of Enanta’s website at www.enanta.com.
A replay of the webcasts will be available approximately two hours
following the presentations and will be archived for approximately 30
days.
About Enanta
Enanta Pharmaceuticals is a research and
development-focused biotechnology company that uses its robust
chemistry-driven approach and drug discovery capabilities to create
small molecule drugs in the infectious disease field. Enanta is
discovering and developing novel inhibitors designed for use against the
hepatitis C virus (HCV). These inhibitors include members of three
direct acting antiviral (DAA) inhibitor classes – protease (partnered
with AbbVie), NS5A (partnered with Novartis) and nucleotide polymerase –
as well as a host-targeted antiviral (HTA) inhibitor class targeted
against cyclophilin. Additionally, Enanta has created a new class of
antibiotics, called Bicyclolides, for the treatment of multi-drug
resistant bacteria, with a focus on developing an intravenous and oral
treatment for hospital and community MRSA (methicillin-resistant Staphylococcus
aureus) infections.
Copyright Business Wire 2013